Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades C4 Therapeutics to Neutral, Lowers Price Target to $15

JP Morgan analyst Eric Joseph downgrades C4 Therapeutics (NASDAQ:CCCC) from Overweight to Neutral and lowers the price target from $22 to $15.
byBenzinga Newsdesk
November 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Eric Joseph downgrades C4 Therapeutics (NASDAQ:CCCC) from Overweight to Neutral and lowers the price target from $22 to $15.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Akari Therapeutics Presents Poster On Progress In Pre-Clinical Development Of Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy At The 4th Annual Dry AMD Therapeutic Development Conference

By Benzinga Newsdesk
November 16, 9:18 AM
Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of

AKTX

Read More

Agrify’s CEO Optimistic Despite YoY Decline In Q2 Revenue, Gross Profit: A Path To Profitability?

By Jelena Martinovic
December 12, 11:34 AM
Agrify Corporation (NASDAQ: AGFY) announced on Tuesday second quarter financial results for the three months ended June 30, 2023, revealing a 73% year-over-year decrease in revenue to $5.1 million.Raymond Chang, chairman and CEO Officer at Agrify, provided more insight into what the company's focus was during the previous period."As described in our prior earnings release, the four key priorities for the Company are (1) restructuring our balance sheet, (2) reducing our costs and headcount, (3) improving our product offerings, and (4) getting our key products CE-certified for international markets," Chang said.

AGFY